Lv11
10 积分 2025-07-22 加入
Drug Interactions of Clinical Importance
1个月前
已完结
CHAPTER 9. Parenteral Delivery of Therapeutic Proteins, Peptides and Small Molecules Using Biodegradable Silica
1个月前
已关闭
CHAPTER 9: Parenteral Delivery of Therapeutic Proteins, Peptides and Small Molecules Using Biodegradable Silica
1个月前
已关闭
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
1年前
已完结
Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
1年前
已完结
Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study
1年前
已完结
<p>The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis</p>
1年前
已关闭
Hepatic adverse events associated with anaplastic lymphoma kinase tyrosine kinase inhibitors: a disproportionality analysis based on FAERS Database and analysis of drug-gene interaction network
1年前
已完结
Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer
1年前
已完结
皖公网安备34019202002308
